LOE and behold, massive BMS merger near with Astrazeneca?
· randy osborne
AI Briefing
- • Astrazeneca and Bristol Myers Squibb (BMS) are reportedly in talks for a massive merger.
- • A complementary pipeline could benefit both companies, according to Leerink analyst David Risinger.
- • Both firms are keeping mum about the potential deal, sparking Wall Street interest.
Context
A potential merger between Astrazeneca plc and Bristol Myers Squibb Co is being discussed. Leerink analyst David Risinger stated that the pipelines of the two companies are "highly complementary". Rumors of a possible deal have been circulating on Wall Street.
The merger could benefit both Astrazeneca and Bristol Myers Squibb, according to David Risinger. Neither company has commented on the rumors, with both firms keeping quiet about the potential setup.
Advertisement